FGFR1 and non-small cell lung carcinoma: Promising results were obtained in 40 advanced Sq-NSCLC patients with FGFR1-3 overexpression (NCT03762122) treated with rogaratinib; two patients (5.6%) achieved PR (in one, for > 16 months) and SD was achieved in 64% (51, 59).